Dimitri BEDO

Interne en Nephrologie-Dialyse-Transplantation au CHU de Strasbourg, intérêt pour la recherche en médecine cardio-rénale et la transplantation rénale.

[CKJ @CKJsocial]

Arteriovenous fistula for haemodialysis as a predictor of de novo heart failure in kidney transplant recipients

https://t.co/ABY6niRYJe

[Circulation @CircAHA]

#ACC25 #CircSimPub In a prespecified analysis of the SOUL trial, oral semaglutide reduced MACE outcomes independently of concomitant SGLT2i use in patients with T2DM and ASCVD and/or CKD. GLP1-RA and SGLT2i can be saf... https://t.co/cnE6vCwLvD #AHAJournals @Dr_Birkenfeld @RBusui

[KIReports @KIReports]

Early and Sensitive Detection of #Cisplatin Induced #KidneyInjury Using Novel #Biomarkers

#VisualAbstract by @jmteakell

https://t.co/CtBMmkIshg

[SNINephrologie @SNINephrologie]

Le SNIN tient à vous souhaiter une belle et heureuse année 2025 🥳
On en profite pour vous présenter le bureau 2024/2025 ✨ (un peu tardivement, mais mieux vaut tard que jamais !!)
Le meilleur reste à venir ! 🫡

[Dimitri BEDO @DimitriBedo]

Équipe très sympathique et compétente !!!

[CJ Néphro @CJNephro]

Offre d'emploi : CH de Dole https://t.co/pY0dwCYLSx

[Hans-Joachim Anders @hjanders_hans]

Now online in @NDTsocial

Tissue fibrosis in cardiorenal syndrome: crosstalk between heart and kidneys

🧐 The repair process in cardiorenal injury involves a regenerative phase characterized by proliferation and polyploidization.

▶️https://t.co/4DU1OAktiU

[Dimitri BEDO @DimitriBedo]

@c_massoumipour @MaanaouiMehdi @amjtransplant @CR2TI_Nantes @CHUnantes @BranchereauJu @CantarovichD @SFTfrancophone Bravo !

[Académie de médecine de France @acadmed]

LAURÉATS 2024]
🏅Félicitations à @RaphaelCarapito, lauréat du prix Éloi Collery pour ses travaux sur la #pathologie #alloimmunes et #autoimmunes/#inflammatoires

@CHRUStrasbourg @inserm

🛜 https://t.co/fNmn6ec9Iu

[Dimitri BEDO @DimitriBedo]

Un grand big-up et toutes mes félicitations au meilleur des nephrovirologues!

[Académie de médecine de France @acadmed]

[LAURÉATS 2024]
🏅Félicitations à @ilies_benotmane, lauréat du prix Drieu-Cholet pour ses travaux sur la #transplantation #rénale #Covid"

@CHRUStrasbourg @SFTJuniors @Inserm

🛜 https://t.co/fNmn6ec9Iu

[European Society of Cardiology Journals @ESC_Journals]

Type 2 myocardial infarction: challenges in diagnosis and treatment. Read this State-of-the-Art Review just published in #EHJ 👉 https://t.co/GYc4J0SEme

@RoccoMontone @ehj_ed

[JAMA @JAMA_current]

Atrial fibrillation (AF) is associated with increased rates of stroke, heart failure, and mortality. This narrative review examines the epidemiology, pathophysiology, diagnosis, and treatment of AF.

https://t.co/Sgc974ACYv

[NDT @NDTsocial]

🧐Selected from our joint @ERAkidney and @escardio Cardio-Kidney Collection:

https://t.co/mmYxSAismq

➡️Proximal versus distal diuretics in congestive heart failure

🔓https://t.co/1zv1iEl5Bc

[NDT @NDTsocial]

The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis

🆓https://t.co/YxNaEE6XiI

[KIReports @KIReports]

SGLT2 Inhibitor #SGLT2i in #Diabetic and #NonDiabetic Renal #Transplant Recipients

#VisualAbstract by @DrPSVali

https://t.co/KylV8oLllW

[NDT @NDTsocial]

Changing treatment paradigms for membranous nephropathies

🆓https://t.co/hjiymJE1af

[Dimitri BEDO @DimitriBedo]

Risque bien de changer les pratiques !

[NEJM @NEJM]

Original Article: Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma (AQUILA) https://t.co/XMTnn80k2u

#ASH24 | @ASH_hematology

[NEJM @NEJM]

Original Article: Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease (EPIC-CAD) https://t.co/13c46bpne0

Editorial: Atrial Fibrillation and Stable Coronary Artery Disease https://t.co/kKganMwBDx

#Cardiology

[Abdulla A. Damluji, MD, PhD @DrDamluji]

Intensive Blood-Pressure Control in Patients with Type 2 Diabetes: @NEJM

🥸 Day 3 of #AHA24 continues: Great work @AHAScience

😱 Let's summarize BPROAD trial

👇👇👇

[Abdulla A. Damluji, MD, PhD @DrDamluji]

Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity: @NEJM

🥸The SUMMIT trial - @AHAScience

😱 Summary

👇👇👇

[NEJM @NEJM]

In the CLEAR randomized trial involving patients with acute myocardial infarction, colchicine did not decrease the risk of major adverse cardiovascular events over a median follow-up period of 3 years. Full trial results: https://t.co/k3fRIyyFpd